Bahrain replaced its device traceability hub with a national programme. Registration for anyone placing product on that market opened in April 2026.
NHRA Circular No. 5 of 2026, issued on 15 March 2026, introduces a national traceability programme for medical devices and supplies placed on the Bahraini market. Mandatory registration for manufacturers, authorised representatives, wholesalers and other exporters opened in April 2026, with the platform launch and the associated regulatory requirements planned for July 2026. It follows Circular No. 16 of 2025, which terminated the incumbent NHRA-MVC traceability hub provider. Healthcare institutions and other local operators come in during later phases, so the compliance perimeter is set to widen.
What a board member needs before the next meeting on this.
- The programme is named, dated and signed. NHRA Circular No. (5) 2026, dated 15 March 2026 and issued from the Chief Executive Office under the signature of Dr Ahmed Mohammed Al Ansari, introduces a national traceability programme for medical devices and medical supplies placed on the Bahraini market.
- Phase one captures the point of entry. The initial phase applies to manufacturers, authorised representatives, wholesalers and other exporters placing devices or supplies on the market. NHRA identifies these as the primary entry point into the national supply chain and therefore the first participants required to engage.
- Two dates were published, both now passed. Mandatory registration for those stakeholders opened in April 2026. The platform launch and the commencement of the regulatory requirements associated with the programme were planned for July 2026. An entity placing product on that market today is inside a live compliance perimeter.
- It follows a provider termination, not a routine upgrade. Circular No. (16) 2025, dated 8 October 2025, notified all invoicing companies and dispensers of the termination of the current NHRA-MVC traceability hub provider. The new programme is the replacement, which is why it arrives as a full national platform rather than an amendment.
On 15 March 2026 Bahrain's National Health Regulatory Authority issued Circular No. (5) 2026 from its Chief Executive Office, addressed to all medical device and medical supply manufacturers, authorised representatives, wholesalers and other exporters placing products on the Bahraini market (NHRA Circular 5/2026; NHRA announcements index). It introduces a national traceability programme for medical devices and supplies. The circular is short and reads administratively, which is how a market-access requirement tends to arrive.
The first phase captures whoever places product on the market
NHRA states that the initial phase focuses on manufacturers, authorised representatives, wholesalers and other exporters placing medical devices or medical supplies on the Bahraini market, on the reasoning that these stakeholders represent the primary entry point into the national supply chain and are therefore the first participants required to engage with the framework.
The distinction that matters commercially is which entity in a supply chain is treated as placing the product. A European or Asian manufacturer selling through a Bahraini authorised representative, and a regional distributor holding the registration on the manufacturer's behalf, are differently positioned under that language, and most distribution agreements written before March 2026 will not allocate the obligation because it did not exist when they were drafted.
The dates have passed, which is the point
The circular sets out a phased implementation with two published milestones. April 2026 was the opening of mandatory registration for authorised representatives, manufacturers, wholesalers and other exporters. July 2026 was the planned launch of the NHRA Medical Devices and Supplies Traceability Platform and the commencement of the regulatory requirements associated with the programme. Both are now behind us.
An entity supplying that market today is operating inside a live perimeter rather than preparing for a future one, and the question is whether registration was completed rather than whether it is required. NHRA said that further information on registration procedures and technical onboarding would follow through subsequent circulars, so the announcements index is the place to watch rather than a mailing list.
The legal basis is named, and so is the fee instrument
The programme is implemented under Law No. (38) of 2009 establishing the National Health Regulatory Authority, Resolution No. (48) of 2020 on Medical Devices and Products Quality Control, and Resolution No. (24) of 2021 amending Resolution No. (20) of 2016 regarding the determination of fee categories for private healthcare institutions.
The presence of the fee-categories resolution in the legal basis of a traceability programme is worth noting on its own. A registration obligation grounded partly in a fee instrument carries a cost that is set administratively and can be revised administratively, which belongs in a distributor's cost model rather than in a footnote.
The perimeter is designed to widen
NHRA states that participation of additional in-country supply chain stakeholders, including healthcare institutions and other local economic operators that do not fall under the definition of manufacturers, will be progressively incorporated in later implementation phases, with further guidance to be issued in due course. For a distributor, that means the counterparties it sells to will eventually be inside the same system, and the data quality of what it submits today becomes the data its hospital customers reconcile against tomorrow.
The Authority also says it will provide guidance and support during onboarding to maintain continuous availability of devices and supplies, which is the regulator acknowledging that a traceability cut-over can interrupt supply if it goes badly. That is a supply-continuity risk worth naming in a board paper covering the Bahraini book.
Why this sits in a deal file
Bahrain is a small market that GCC distributors often carry as an adjunct to Saudi or UAE operations, and adjunct markets are where registration lapses live. A buyer pricing a regional distribution business should treat the Bahraini registrations as a discrete diligence item now rather than a schedule entry, because the programme replaced an incumbent hub provider terminated under Circular No. (16) 2025 of 8 October 2025 and the transition is recent enough that gaps will not yet have surfaced as enforcement. A distribution agreement silent on who registers, over a product file that has never been mastered to a platform standard, is the ordinary shape of this problem.
Four questions for anyone supplying Bahrain
- Is the entity that actually places product on the Bahraini market registered under the programme, and is that the manufacturer, the authorised representative, or a wholesaler acting for both?
- Where the authorised representative is a third party, whose obligation is registration under the circular, and does the distribution agreement allocate it or leave it unstated?
- What master data does the platform require per product, and does the current article file carry it at the standard the platform expects, or is that a data remediation exercise?
- If a later phase brings healthcare institutions and other local operators into scope, which of the group's Bahraini counterparties will need to onboard, and who bears that cost under existing contracts?
The Monday work is finite. Establish which legal entity places each product line on the Bahraini market and confirm its registration status directly rather than through the commercial contact. Read the distribution agreements for who carries the obligation and amend the ones that are silent. Then assess whether the product master data meets the platform's requirements or needs remediation before the next phase pulls your customers in. That regulatory and transaction work is where our transactions and capital markets practice begins.
This brief covers one instrument. The UAE healthcare regulatory tracker carries the full set — DoH, DHA, EDE and the other emirates — with what each one changes and when it takes effect.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.